Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Jan;39(1):1-11.
doi: 10.1097/IAE.0000000000002327.

ANGIOID STREAKS: A Comprehensive Review From Pathophysiology to Treatment

Affiliations
Review

ANGIOID STREAKS: A Comprehensive Review From Pathophysiology to Treatment

Irini Chatziralli et al. Retina. 2019 Jan.

Abstract

Purpose: To stratify the literature on angioid streaks, from pathophysiology to treatment.

Methods: Review of the current literature.

Results: Angioid streaks are crack-like dehiscences of Bruch membrane, which may coexist with systemic diseases, such as pseudoxanthoma elasticum, Paget disease, Ehlers-Danlos syndrome, hemoglobinopathies, or other diseases of the collagen. Various diagnostic methods, including infrared and red-free retinography, autofluorescence, optical coherence tomography, fluorescein angiography, and indocyanine green angiography, are useful to diagnose, evaluate, and monitor angioid streaks. Choroidal neovascularization consists of a major complication of angioid streaks leading to visual impairment. Therefore, observation could not be a treatment option. Photodynamic treatment or anti-vascular endothelial growth factor agents have been used for the treatment of angioid streaks, offering promising but short-term results. Currently, the available treatment may limit the disease, but not permanently inactivate it.

Conclusion: This review discusses the epidemiology, pathophysiology, diagnosis, and treatment of angioid streaks, presenting the existing literature on this topic.

PubMed Disclaimer

Comment in

  • Reply.
    Chatziralli IP. Chatziralli IP. Retina. 2019 Dec;39(12):e58-e59. doi: 10.1097/IAE.0000000000002661. Retina. 2019. PMID: 31592883 No abstract available.
  • Correspondence.
    Charbel Issa P. Charbel Issa P. Retina. 2019 Dec;39(12):e56-e58. doi: 10.1097/IAE.0000000000002660. Retina. 2019. PMID: 31592884 No abstract available.

Substances